Pulmonary Cell News

[Bio-Thera Solutions (Business Wire, Inc.)] Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for BAT1706, a proposed biosimilar to Avastin®.

[Science Advances] The authors developed an in situ 3D printing system that estimated the motion and deformation of the target surface to adapt the toolpath in real time. With this printing system, a hydrogel-based sensor was printed on a porcine lung under respiration-induced deformation.

[Adamis Pharmaceuticals] Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.

[Scientific Reports] Investigators provided evidence supporting the notion that ERK1 and ERK2 have functionally distinct properties and that ERK2, not ERK1, primarily contributed to lung metastasis in a riple negative breast cancer mouse model.